Company Bicycle Therapeutics plc

Equities

BCYC

US0887861088

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for Bicycle Therapeutics plc

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
22.68 ^USD	+0.49%		+3.94%	+25.44%

Apr. 22	European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading	MT
Apr. 19	European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	MT

Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a class of medicines, which it refers to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are therapeutic modality combining the pharmacology usually associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. Its product candidates BT5528, BT8009 and BT1718, are each a Bicycle Toxin Conjugate (BTC). BT5528 is a second-generation BTC designed to target Ephrin type A receptor 2 (EphA2). BT8009 is a second-generation BTC designed to target Nectin-4, a validated tumor antigen. BT1718 is being developed to target tumors that express Membrane Type 1 matrix metalloproteinase (MT1 MMP). Its product candidates BT7480 and BT7455, are each a Bicycle tumor-targeted immune cell agonist (TICA). The Company is also focused on additional therapeutic areas other than its wholly owned oncology portfolio.

Number of employees: 284

USD in Million	2022	Weight	2023	Weight	Delta
Chemically Synthesized Medicines 100.0 %	14	100.0 %	27	100.0 %	+86.52%

USD in Million	2022	Weight	2023	Weight	Delta
United Kingdom 100.0 %	14	100.0 %	27	100.0 %	+86.52%

Managers	Title	Age	Since
Kevin Lee CEO	Chief Executive Officer	55	15-08-31
Alethia Young DFI	Director of Finance/CFO	45	23-07-16
Alistair Milnes COO	Chief Operating Officer	50	20-12-31
Michael Skynner CTO	Chief Tech/Sci/R&D Officer	55	15-12-31
Nicholas Keen CTO	Chief Tech/Sci/R&D Officer	56	16-12-31
David Borah IRC	Investor Relations Contact	-	21-03-31
Jennifer Perry PRN	Corporate Officer/Principal	-	-
Travis Thompson AUD	Comptroller/Controller/Auditor	-	18-03-31
Zafar Qadir LAW	General Counsel	-	20-04-22
Santiago Arroyo PRN	Corporate Officer/Principal	64	23-03-30

Members of the board	Title	Age	Since
Pierre Legault CHM	Chairman	63	19-03-17
Jose-Carlos Gutiérrez-Ramos BRD	Director/Board Member	61	21-03-16
Richard Kender BRD	Director/Board Member	68	19-07-23
Janice Bourque BRD	Director/Board Member	67	19-07-17
Gregory Winter FOU	Founder	73	08-12-31
Kevin Lee CEO	Chief Executive Officer	55	15-08-31
Stephen Sands BRD	Director/Board Member	67	Feb. 19

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	37,880,303	4,333,333 ( 11.44 %)	0	11.44 %

Name	Equities	%	Valuation
Baker Bros. Advisors LP 18.59 %	7,041,176	18.59 %	175 M $
Paradigm BioCapital Advisors LP 9.786 %	3,707,001	9.786 %	92 M $
Deep Track Capital LP 9.215 %	3,490,506	9.215 %	87 M $
Jefferies LLC 5.143 %	1,948,000	5.143 %	49 M $
Baker Bros. Advisors LP 4.726 %	1,790,390	4.726 %	45 M $
Tybourne Capital Management (HK) Ltd. 4.357 %	1,650,320	4.357 %	41 M $
First Light Asset Management LLC 4.093 %	1,550,471	4.093 %	39 M $
Armistice Capital LLC 4.055 %	1,536,000	4.055 %	38 M $
Morgan Stanley Capital Services LLC 2.717 %	1,029,225	2.717 %	26 M $
POLAR CAPITAL HOLDINGS PLC 2.652 %	1,004,535	2.652 %	25 M $

Name	Equities	%	Valuation
Cambridge Innovation Capital Ltd 5.917 %	1,751,437	5.917 %	44 M $
GSK PLC 5.168 %	1,529,561	5.168 %	38 M $
Baker Bros. Advisors LP 2.789 %	825,418	2.789 %	21 M $
Kevin Lee 1.308 %	387,270	1.308 %	10 M $
Gregory Winter 0.6104 %	180,677	0.6104 %	4 M $
Michael Skynner 0.3206 %	94,884	0.3206 %	2 M $
Alistair Milnes 0.2441 %	72,241	0.2441 %	2 M $
Nicholas Keen 0.2358 %	69,803	0.2358 %	2 M $
Nigel Crockett 0.1614 %	47,761	0.1614 %	1 M $
Santiago Arroyo 0.1318 %	39,000	0.1318 %	971 100 $

Name	Equities	%	Valuation
Baker Bros. Advisors LP 14.28 %	672,067	14.28 %	17 M $

Bicycle Therapeutics Plc

Granta Park Great Abington Portway Building

CB21 6GS, Cambridge

+44 1223 261 503

http://bicycletherapeutics.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

22.57 USD

Average target price

43.99 USD

Spread / Average Target

+94.89%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
BICYCLE THERAPEUTICS PLC	+25.44%	963M
VERTEX PHARMACEUTICALS INCORPORATED	-0.49%	103B
REGENERON PHARMACEUTICALS, INC.	+3.31%	96.73B
ARGENX SE	+1.66%	21.31B
BIONTECH SE	-16.16%	21.21B
GENMAB A/S	-6.82%	18.79B
WUXI APPTEC CO., LTD.	-41.41%	16.37B
BEIGENE, LTD.	-22.87%	13.68B
NEUROCRINE BIOSCIENCES, INC.	+6.32%	13.44B
SAREPTA THERAPEUTICS, INC.	+21.46%	10.98B

Bio Therapeutic Drugs